Related references
Note: Only part of the references are listed.A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK
Stephen M. Montgomery et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility
Stephen M. Montgomery et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY
Andreas-Antonios Roussakis et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Advantages and disadvantages of discrete-event simulation for health economic analyses
J. Jaime Caro et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis
T. Derfuss et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
Tuan Dong-Si et al.
JOURNAL OF NEUROVIROLOGY (2015)
Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom
Felicity Allen et al.
VALUE IN HEALTH (2015)
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England
Maciej J. Maruszczak et al.
JOURNAL OF MEDICAL ECONOMICS (2015)
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk
Bhupendra O. Khatri et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
Eva Havrdova et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Orla Tuohy et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database
I. S. Mackenzie et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches
Shien Guo et al.
PHARMACOECONOMICS (2014)
When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES
Jonathan Karnon et al.
PHARMACOECONOMICS (2014)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Natural, innate improvements in multiple sclerosis disability
Helen Tremlett et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Modeling Good Research Practices-Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
J. Jaime Caro et al.
VALUE IN HEALTH (2012)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2009)
The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK
Michelle Orme et al.
VALUE IN HEALTH (2007)
A taxonomy of model structures for economic evaluation of health technologies
Alan Brennan et al.
HEALTH ECONOMICS (2006)
Health state utilities for metastatic breast cancer
A. Lloyd et al.
BRITISH JOURNAL OF CANCER (2006)
Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia
A Gordois et al.
CLINICAL TRANSPLANTATION (2006)
An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population
S Petrou et al.
HEALTH ECONOMICS (2005)
The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): Descriptive analysis from the first 20,000 subjects
CJ Currie et al.
VALUE IN HEALTH (2005)
Share Paper
